Drug intelligence / Profile preview

amoxicillin + erythromycin

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Amoxicillin + erythromycin is an antibiotic combination therapy that combines two different classes of antibiotics. Amoxicillin is a penicillin-class antibiotic that inhibits bacterial cell wall synthesis, while erythromycin is a macrolide antibiotic that works by stopping bacterial protein synthesis. This combination has been studied for treating various infections, particularly pneumonia and Legionella infections, where it may provide broader coverage than either agent alone.

Targets

23S rRNA (23S ribosomal RNA)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on amoxicillin + erythromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + erythromycin.

Explore the full profile